A股市场今天(1月8日)上午主要股指涨跌互现，国防军工板块领涨，券商股则集体陷入调整。 概念板块方面，今天上午A股市场和港股市场的脑机接口概念均重新活跃，相关概念指数涨幅超过4%，多股大涨。不 过，近日已有不少上市公司澄清或提示相关炒作风险。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▲ | | --- | --- | --- | --- | --- | | 002945 | 华林证券 | 16.92 | -1.88 | -10.00% | | 600909 | 华安证券 | 7.15 | -0.38 | -5.05% | | 600599 | *ST熊猫 | 8.54 | -0.45 | -5.01% | | 600053 | 九鼎投资 | 20.67 | -0.89 | -4.13% | | 601688 | 华泰证券 | 24.20 | -1.02 | -4.04% | | 601377 | 兴业讲券 | 7.32 | -0.30 | -3.94% | | 000776 | 广发证券 | 22.28 | -0.88 | -3.80% | | 601211 | 国泰海通 | 21.52 | -0 ...

Core Viewpoint - The "brain-computer interface" has become a market hotspot, leading to significant stock price increases for several companies, which has drawn regulatory scrutiny [1][2]. Group 1: Regulatory Actions - On January 7, the Shanghai Stock Exchange issued regulatory warnings to companies including Yahui Long and Yingjixin for inaccurate and incomplete disclosures related to their "brain-computer interface" business [1][2]. - Yahui Long's stock price rose by 6.52% on January 6, with trading volume increasing by 299% compared to the previous trading day [2]. - Yingjixin's response to investor inquiries about its IPA1299 chip, which is designed for high-precision measurement of biological electrical signals, led to regulatory scrutiny due to misleading implications about its market readiness and performance [2][3]. Group 2: Company Disclosures - Yahui Long disclosed a strategic cooperation agreement with Shenzhen Brain Machine Star Chain Technology Co., stating that the latter is a leading company in both non-invasive and invasive technology paths, which prompted regulatory inquiries [1]. - Following regulatory pressure, Yahui Long clarified that Brain Machine Star Chain is currently focused on non-invasive technology and that its products are still in early research and development stages [1][3]. - Yingjixin's IPA1299 chip is a joint product with a subsidiary and is still in the market cultivation phase, with no significant impact on the company's performance yet [3]. Group 3: Market Reactions - Several companies, including Weisi Medical, Xiangyu Medical, and Mailande, experienced significant stock price increases, with cumulative price deviations exceeding 30% over two consecutive trading days, triggering abnormal trading notifications [3][4]. - Despite their involvement in the brain-computer interface sector, these companies primarily focus on rehabilitation medical devices, and their related business activities are still in the research or early exploration stages, not significantly impacting their operational performance in the short term [4].

Core Insights - The brain-computer interface (BCI) concept continues to gain momentum, with related stocks experiencing significant increases, particularly in the medical device sector [1][2]. Group 1: Market Performance - The medical device index ETF (159898) has seen a rise of over 1.94%, with approximately 37 million yuan in net inflow as of the latest report [1]. - Key stocks such as Kewei Medical surged over 19%, while others like Shuoshi Bio and Lepu Medical increased by over 13% and 6% respectively [1]. Group 2: ETF and Index Details - The medical device index ETF (159898) tracks the CSI All Share Medical Device Index, with a BCI concept weight of about 24% [2][3]. - The ETF's latest scale is 536 million yuan, and it has outperformed its peers since 2025 [2]. Group 3: Industry Growth and Projections - The global BCI market size grew from 1.2 billion USD in 2019 to nearly 2 billion USD in 2023, with a compound annual growth rate (CAGR) exceeding 13% [4]. - Projections indicate that the global BCI industry could reach 7.63 billion USD by 2029, with a CAGR of over 25% from 2024 to 2029 [4]. Group 4: Investment Opportunities - The BCI sector is currently experiencing a high-growth phase driven by technological breakthroughs, policy support, and ecosystem collaboration [7]. - The medical field is identified as the most mature and largest segment for BCI commercialization, making it a key area for investment [7].

Core Viewpoint - Companies YHLO and Ingetech received regulatory warnings from the Shanghai Stock Exchange due to inaccurate and incomplete disclosures regarding their involvement in the "brain-computer interface" sector [1] Group 1: YHLO - YHLO voluntarily disclosed a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., stating collaboration in product development, market promotion, and equity investment [2] - Following regulatory prompting, YHLO issued a supplementary announcement clarifying that Brain Machine Starlink's current research products focus solely on non-invasive technology, with no invasive technology development [3] - The Shanghai Stock Exchange criticized YHLO for inconsistent statements regarding the technology paths of its partner and for failing to adequately disclose risks related to cooperation feasibility and uncertainties [3] Group 2: Ingetech - Ingetech claimed its IPA1299 chip, designed for high-precision measurement of human bioelectric signals, could compete with leading overseas chip products [4] - After regulatory intervention, Ingetech clarified that the IPA1299 chip is co-developed with a subsidiary and is still in the market cultivation phase, with no significant impact on company performance yet [4] - The Shanghai Stock Exchange noted that Ingetech's disclosures did not accurately reflect the product's development status, sales scale, and significant technical differences from international invasive brain-computer interfaces [4] Group 3: Industry Context - Multiple companies, including Xinghuan Technology and Bibeite, have issued risk warnings due to significant stock price fluctuations, emphasizing the need for rational investment decisions [5] - Companies involved in the brain-computer interface sector have highlighted that their products are primarily in the research or market cultivation stages, with a focus on non-invasive routes, contrasting with the invasive methods prevalent internationally [6] - Industry analysts predict that medical applications of brain-computer interfaces may take 3 to 5 years for approval, with consumer-grade devices facing longer development cycles and challenges in user experience and market acceptance [7]

亚辉龙 ： 关键 表述前后不一致 亚辉龙 在 1月6日收盘后自愿披露与深圳脑机星链科技有限公司 的 《战略合作框架协议》， 称双方将在产品研发、市场推广以及股权投资等方面开展合作，并披露后者为"深耕非侵入式 与侵入式双技术路径的领先企业"。 经上交所督促，亚辉龙于 当日 晚间又发布《关于自愿披露签署战略合作框架协议的补充公 告》。 【导读】亚辉龙、英集芯因涉及"脑机接口"信息披露不准确收到监管函 中国基金报记者 牛思若 1月7日晚间， 脑机接口概念股 亚辉龙、英集芯 及其 有关责任人被上交所予以监管警示， 均因 在披露涉及"脑机接口"业务信息时存在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 处理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集示 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 20 ...

Summary of Xiangya Medical's Conference Call Company Overview - **Company**: Xiangya Medical - **Industry**: Brain-Computer Interface (BCI) and Rehabilitation Equipment Key Points and Arguments Product Development and Market Entry - Xiangya Medical has launched a series of brain-computer interface products, including EEG machines and new products with multimodal technology, covering disease diagnosis and patient rehabilitation. Over 10 non-invasive brain-controlled products are expected to receive registration by Q1 2026, with plans to launch 70-80 new products by the end of the year, totaling over 100 products in the market [2][3][4] - The brain-controlled products have entered over 500 top hospitals, with a target of over 1,000 hospitals by the Lunar New Year of 2027, primarily through clinical research, scientific projects, or procurement methods [2][4] - New devices are classified as Class II medical devices, which do not require clinical trials, representing an upgrade to traditional rehabilitation equipment. The active rehabilitation effect is over 20% better than traditional passive rehabilitation methods, with this percentage continuously improving [2][6] Revenue and Growth Projections - Xiangya Medical anticipates approximately 100 million yuan in revenue from the brain-computer interface business by the end of 2026, despite a macroeconomic downturn, projecting single-digit growth in 2026 and a return to double-digit growth in 2027 [3][19] - The company has established a goal of achieving over 100 million yuan in revenue based on the progress of registration certificates and hospital procurement processes [19] Competitive Advantages - Xiangya Medical has a significant competitive edge in the BCI field due to 10 years of technical accumulation, including hardware, algorithms, and data collection precision. All key components are self-developed, which reduces costs and enhances compatibility with rehabilitation devices [11][12] - The company is the only one in the rehabilitation industry that simultaneously produces self-developed data collection devices and rehabilitation equipment, making it difficult for competitors to catch up quickly [11] Market Demand and Policy Support - There is strong demand and procurement willingness for BCI devices in top hospitals, driven by government policies supporting the industry. Nearly 20 provinces have published related charging directories, accelerating the clinical application of BCI devices [9][10] - The pricing for BCI rehabilitation training is affordable, ranging from tens to over a hundred yuan, which aligns with clinical needs and enhances the market's acceptance [10][16] Non-Medical BCI Products and Future Plans - Xiangya Medical is also developing non-medical BCI products focusing on attention, meditation, and insomnia, with plans to launch consumer-grade products in 2026 [22] - The company has established a robotics research center to focus on rehabilitation robots, with plans for lightweight portable exoskeleton products expected to receive registration in the first half of 2026 [23][25] Clinical Integration and Regulatory Environment - The integration of clinical specialties is increasingly recognized despite current procurement pressures. The company promotes a comprehensive clinical rehabilitation model, which is expected to improve hospital revenue structures in the long term [31] - The DRG system positively impacts the rehabilitation business, with evidence showing that rehabilitation revenue in high-level hospitals can account for one-third of total income [32][33] Conclusion - Xiangya Medical is positioned for significant growth in the BCI and rehabilitation equipment market, leveraging its technological advancements, strong market demand, and supportive government policies to achieve its revenue goals and expand its product offerings in both medical and non-medical applications [3][19][22]

Core Insights - The brain-computer interface (BCI) market is poised for significant growth, driven by advancements in technology and supportive policies, with a projected global market size reaching $40 billion by 2030 and $145 billion by 2040 in medical applications alone [3][4]. Industry Overview - BCI technology connects the brain with external devices for information exchange, categorized into three types: invasive, semi-invasive, and non-invasive, each with varying signal quality and safety [2]. - The medical sector is the primary application area for BCI technology, accounting for 56% of its applications, significantly improving the quality of life for patients with severe motor disabilities [3]. Market Dynamics - The A-share market has seen a surge in BCI-related stocks, with over 50 billion yuan flowing into the sector, indicating strong investor interest following announcements from Neuralink about large-scale production plans [1][5]. - Companies like Beiyikang, Sanbo Neurosurgery, and Aipeng Medical are actively involved in BCI development, with significant advancements in both invasive and non-invasive technologies [5][6]. Investment Landscape - Neuralink's recent funding round raised $650 million, valuing the company at $9 billion, highlighting the market's optimism for invasive BCI technologies [8]. - The BCI sector in China has experienced nearly 100 financing events in the past five years, with total funding exceeding 10 billion yuan, indicating robust investment activity [8]. Challenges and Considerations - Despite the optimistic outlook, the BCI industry faces challenges such as high development costs, lengthy clinical validation processes, and reliance on imported core components [9]. - The commercial viability of BCI products is still in its early stages, with a need for clearer pathways to market for both invasive and non-invasive products [9].

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑机接口"业务信息时存 在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 外理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集示 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的地完书 | | | 亚辉龙1月6日股价上涨6.52%、成交量较前一个交易日增长299%。当天收盘后，该公司自愿披露与深圳脑机星链科技有限公司签订《战略合作框架协 议》，称双方将在产品研发、市场推广以及股权投资等方面开展合作，并披露后者为"深耕非侵入式与侵入式双技术路径的领先企业"。该公告披露后引 发市场关注，上交所火速下发问询函，要求公司说明合作具体情况。在监管督促下， ...

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑 机接口"业务信息时存在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 处理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集芯 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的决定书 | | | 亚辉龙1月6日晚自愿披露与脑机接口相关公司的框架协议，当晚收到上交所问询函，要求其进一步核实情况。另一家科创板公司英集芯也在1月 6日通过投资者互动平台透露关于脑机接口芯片领域的早期投资布局，因内容语焉不详，易引起误导，被上交所下发监管工作函。当前，两家公 司均已补充披露公告说明业务风险。 近期，"脑机接口"成为市场热点，多家公司股价连续涨停，引发监 ...

Core Viewpoint - Xiangyu Medical announced that its stock price experienced a cumulative deviation of 30% over three consecutive trading days on December 31, 2025, January 5, and 6, 2026 [1] Group 1: Business Overview - The company has established a comprehensive technology layout in the non-invasive brain-computer interface field, differing from mainstream invasive technology routes [1] - Although the company has formed a preliminary foundation in technology, products, and channels, the promotion of related product bidding and sales has been lagging [1] Group 2: Sales and Revenue - As of the end of 2025, the non-invasive brain-computer interface business has not achieved scaled sales, contributing minimally to the company's overall revenue [1]